AxoGen (AXGN) – Investment Analysts’ Recent Ratings Changes

Several analysts have recently updated their ratings and price targets for AxoGen (NASDAQ: AXGN):

• 6/6/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.
• 5/29/2026 – AxoGen had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 5/29/2026 – AxoGen was upgraded by Zacks Research from “strong sell” to “hold”.
• 5/23/2026 – AxoGen was upgraded by Wall Street Zen from “hold” to “buy”.
• 5/2/2026 – AxoGen was downgraded by Wall Street Zen from “buy” to “hold”.
• 4/29/2026 – AxoGen had its “outperform” rating reaffirmed by Raymond James Financial, Inc.. They now have a $48.00 price target on the stock.
• 4/29/2026 – AxoGen had its price target raised by Canaccord Genuity Group Inc. from $45.00 to $50.00. They now have a “buy” rating on the stock.
• 4/29/2026 – AxoGen had its price target raised by HC Wainwright from $39.00 to $50.00. They now have a “buy” rating on the stock.
• 4/29/2026 – AxoGen had its “outperform” rating reaffirmed by Citigroup Inc..
• 4/29/2026 – AxoGen had its price target raised by Wells Fargo & Company from $40.00 to $48.00. They now have an “overweight” rating on the stock.
• 4/29/2026 – AxoGen had its price target raised by Citizens Jmp from $42.00 to $50.00. They now have a “market outperform” rating on the stock.
• 4/27/2026 – AxoGen was downgraded by Zacks Research from “hold” to “strong sell”.
• 4/24/2026 – AxoGen was given a new $45.00 price target by Canaccord Genuity Group Inc..
• 4/23/2026 – AxoGen had its price target raised by Lake Street Capital from $40.00 to $50.00. They now have a “buy” rating on the stock.

Insider Activity

In other news, Director John Johnson sold 11,050 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $43.26, for a total value of $478,023.00. Following the completion of the sale, the director owned 11,050 shares in the company, valued at $478,023. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Kathy Johnson Weiler sold 16,344 shares of the stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $44.09, for a total transaction of $720,606.96. Following the completion of the sale, the director owned 16,344 shares of the company’s stock, valued at approximately $720,606.96. This represents a 50.00% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 34,262 shares of company stock worth $1,440,250. Company insiders own 2.44% of the company’s stock.

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.